Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB706782287
CAS: 706782-28-7
Chemical Name: 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1)
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $4.95 | Total: $495.00 |
1 | 50 | $5.72 | Total: $286.00 |
1 | 25 | $6.71 | Total: $167.75 |
1 | 10 | $7.92 | Total: $79.20 |
1 | 5 | $9.35 | Total: $46.75 |
Molecular Formula | C54H74F2N6O10 |
Molecular Weight | 1005.22 |
CAS Numbers | 706782-28-7 (tartrate) |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | Pimavanserin tartrate; ACP-103; ACP 103; ACP103; Pimavanserin; trade name: Nuplazid. |
IUPAC/Chemical Name | 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1) |
InChl Key | RGSULKHNAKTFIZ-CEAXSRTFSA-N |
InChl Code | InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1 |
SMILES Code | O=C(NCC1=CC=C(OCC(C)C)C=C1)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3.O=C(NCC4=CC=C(OCC(C)C)C=C4)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6.O=C(O)[C@H](O)[C@@H](O)C(O)=O |
References | 1) Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review. Cureus. 2019 Jul 28;11(7):e5257. doi: 10.7759/cureus.5257. Review. PubMed PMID: 31572642; PubMed Central PMCID: PMC6760879. 3) Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review. PubMed PMID: 31159608. |
A none-dopaminergic atypical antipsychotic for the treatment of Parkinson's disease psychosis and schizophrenia